Shira Doron

3.6k total citations · 1 hit paper
81 papers, 2.2k citations indexed

About

Shira Doron is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Shira Doron has authored 81 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 30 papers in Epidemiology and 21 papers in Clinical Biochemistry. Recurrent topics in Shira Doron's work include Antibiotic Use and Resistance (21 papers), Bacterial Identification and Susceptibility Testing (21 papers) and Urinary Tract Infections Management (12 papers). Shira Doron is often cited by papers focused on Antibiotic Use and Resistance (21 papers), Bacterial Identification and Susceptibility Testing (21 papers) and Urinary Tract Infections Management (12 papers). Shira Doron collaborates with scholars based in United States, Lebanon and Italy. Shira Doron's co-authors include David R. Snydman, Lisa Davidson, Sherwood L. Gorbach, Patricia L. Hibberd, Barbara G. Werner, Arthur R. Rabson, Ziad Daoud, Elie Salem Sokhn, Ghassan M. Matar and Robin Ruthazer and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and PEDIATRICS.

In The Last Decade

Shira Doron

74 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk and Safety of Probiotics

2015 617 citations Shira Doron, David R. Snydman Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by Shira Doron

Since Specialization

Citations

This map shows the geographic impact of Shira Doron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shira Doron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shira Doron more than expected).

Fields of papers citing papers by Shira Doron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shira Doron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shira Doron. The network helps show where Shira Doron may publish in the future.

Co-authorship network of co-authors of Shira Doron

This figure shows the co-authorship network connecting the top 25 collaborators of Shira Doron. A scholar is included among the top collaborators of Shira Doron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shira Doron. Shira Doron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Race, ethnicity and risk for colonisation and infection with key bacterial pathogens: a scoping review 2025 ·BMJ Global Health ·Esther E Avendano, (unknown), Nanguneri Nirmala, (unknown), (unknown), (unknown), (unknown), (unknown), Shira Doron, Maya Nadimpalli	1
2	Human Cases of Carbapenemase-Producing Escherichia coli Linked to Spread Between Animals and the Environment in a Veterinary Facility—Massachusetts, USA, 2023 2025 ·Clinical Infectious Diseases ·(unknown), Claire L. Fellman, Paula M. Snippes Vagnone, Melissa Cumming, Jennifer L. Dale, (unknown), (unknown), Catherine Brown, Esther D. Fortes, (unknown), Amanda Beaudoin, (unknown), (unknown), Shira Doron, (unknown), Stephen D. Cole	0
3	Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update 2025 ·Clinical Infectious Diseases ·Michael Klompas, Majdi N. Al‐Hasan, Mayar Al Mohajer, Robert C. Colgrove, Shira Doron, Thomas M. File, Natasha N. Pettit, Michael S. Pulia, Sharon Weissman	0
4	Race and ethnicity and the risk of community-acquired third-generation cephalosporin-resistant uropathogens: a systematic review and meta-analysis 2025 ·Antimicrobial Stewardship & Healthcare Epidemiology ·(unknown), (unknown), Esther E Avendano, (unknown), (unknown), Nanguneri Nirmala, Shira Doron, Maya Nadimpalli	0
5	Effective mitigation of an outbreak of New Delhi metallo-β-lactamase–producing Escherichia coli infections in a small animal veterinary teaching hospital 2025 ·Journal of the American Veterinary Medical Association ·(unknown), Claire L. Fellman, Anne Bergeron, (unknown), Shira Doron, Melissa Cumming, Catherine Brown, (unknown), (unknown), (unknown), Stephen D. Cole	2
6	Risk Factors and Outcomes of Invasive Candida Infections in Heart Transplant Recipients: A Case‐Control Study 2025 ·Clinical Transplantation ·(unknown), (unknown), (unknown), Shira Doron, Jennifer Chow	0
7	Race, ethnicity, and risk for colonization and infection with key bacterial pathogens: a scoping review 2024 ·medRxiv ·Esther E Avendano, (unknown), Nanguneri Nirmala, (unknown), (unknown), (unknown), (unknown), (unknown), Shira Doron, Maya Nadimpalli	2
8	Socioeconomic status and the risk for colonisation or infection with priority bacterial pathogens: a global evidence map 2024 ·The Lancet Microbe ·(unknown), Esther E Avendano, Nanguneri Nirmala, (unknown), (unknown), (unknown), (unknown), (unknown), Shira Doron, Maya Nadimpalli	6
9	Longitudinal trends in 30-day mortality attributable to SARS-CoV-2 among vaccinated and unvaccinated US veteran patients 2023 ·Infection Control and Hospital Epidemiology ·Caitlin A. Trottier, Jennifer La, (unknown), Nathanael R. Fillmore, Paul A. Monach, Shira Doron, Westyn Branch‐Elliman	1
10	Sources of exposure and risk among employees infected with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in a large, urban, tertiary-care hospital in the United States 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Alice Tang, Elena Byhoff, Alysse G. Wurcel, Shira Doron, Ramnath Subbaraman	0
11	Use of expert consensus to develop a shared list of procedures with potential for aerosol generation during the coronavirus disease 2019 (COVID-19) pandemic 2023 ·SHILAP Revista de lepidopterología ·(unknown), Preeti Mehrotra, Lou Ann Bruno‐Murtha, Robert C. Colgrove, Shira Doron, Robert Duncan, Richard T. Ellison, Sarah Haessler, David C. Hooper, Michael Klompas, Cassandra Pierre, Thomas J. Sandora, Erica S. Shenoy, Sharon B. Wright	1
12	“Let a sleeping dog lie”: Perspectives from patients and clinicians about penicillin allergy delabeling 2023 ·Annals of Allergy Asthma & Immunology ·(unknown), Kristin Huang, Shira Doron, (unknown), (unknown), Kimberly G. Blumenthal, Alysse G. Wurcel	6
13	Cycle threshold values and SARS‐CoV‐2: Relationship to demographic characteristics and disease severity 2022 ·Journal of Medical Virology ·(unknown), (unknown), Benjamin Koethe, Shira Doron	11
14	Utility of the cycle threshold in anticipating the next phase of the coronavirus disease 2019 (COVID-19) pandemic 2022 ·Infection Control and Hospital Epidemiology ·(unknown), (unknown), Benjamin Koethe, Shira Doron	3
15	Weekly SARS-CoV-2 screening of asymptomatic kindergarten to grade 12 students and staff helps inform strategies for safer in-person learning 2021 ·Cell Reports Medicine ·Shira Doron, Robin R. Ingalls, (unknown), Jesse S. Boehm, Helen W. Boucher, (unknown), (unknown), (unknown), D T Golenbock, (unknown), David Lussier, Marcia A. Testa, Andrea Ciaranello	18
16	Prospective Observational Study Comparing Sepsis-2 and Sepsis-3 Definitions in Predicting Mortality in Critically Ill Patients 2019 ·Open Forum Infectious Diseases ·Debra D. Poutsiaka, (unknown), (unknown), Jana Hudcova, David J. Tybor, Susan Hadley, Shira Doron, J Reich, David R. Snydman, Stanley A. Nasraway	14
17	Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options 2015 ·Drugs & Aging ·Masako Mizusawa, Shira Doron, Sherwood L. Gorbach	20
18	Evaluation of programmatic changes to an antimicrobial stewardship program with house officer feedback 2012 ·Journal of Evaluation in Clinical Practice ·Steven Y. Hong, Lauren Epstein, Kenneth Lawrence, Lisa Davidson, Ying Taur, (unknown), Shira Doron	4
19	A Multifaceted Approach to Education, Observation, and Feedback in a Successful Hand Hygiene Campaign 2011 ·The Joint Commission Journal on Quality and Patient Safety ·Shira Doron, (unknown), (unknown), (unknown), (unknown), (unknown), Teresa Cheng, (unknown), David R. Snydman, David G. Fairchild	40
20	Lactobacillus GG: Bacteriology and Clinical Applications 2005 ·Gastroenterology Clinics of North America ·Shira Doron, David R. Snydman, Sherwood L. Gorbach	164

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact